WSGR logoWSGR logo

The unique history of Wilson Sonsini Goodrich & Rosati closely traces the birth and evolution of Silicon Valley.

For more than 60 years, Wilson Sonsini has represented technology pioneers associated with virtually every milestone innovation, as well as life sciences trailblazers shaping the future of healthcare.

Today, the firm is synonymous with ushering promising, innovative companies through their business life cycle.

Read More About Us
Image
Image
Image
Image
Image

Wilson Sonsini secured a jury trial win for Google in a case alleging misuse of advertising technology.

Click for additional details.
Careers

We look for the best and brightest of tomorrow and develop careers from the ground up.

Image

News and Featured Insights

News Articles
Wilson Sonsini-Led Matter Shortlisted for GCR Awards 2026
News Articles
2026 WTR 1000 Honors Wilson Sonsini’s Trademark Practice, Attorneys
Newsletters
All Eyes on AI: Regulatory, Litigation, and Transactional Developments - Q3/Q4 2025
Leading Matters
Image
Client Highlights
Wilson Sonsini Advises Remote on Acquisition of Atlas
On January 20, 2026, Remote, the leading global employment operating system, announced it has completed its acquisition of Atlas, an AI-native expense management solution for global teams. The acquisition provides the foundation for a new category of products from Remote to enable customers to offer more holistic and modern employee experiences to their teams.
Learn More
Image
Client Highlights
Wilson Sonsini Advises ESS Tech on $15 Million Registered Direct Offering
On January 29, 2026, ESS Tech, a leading manufacturer of long-duration energy storage systems (LDES) for commercial and utility-scale applications, announced that it has entered into definitive agreements in a registered direct offering with institutional investors for the purchase and sale of approximately $15 million of shares of common stock and pre-funded warrants at a price of $1.75 per share of common stock, which price was a premium to the closing price on January 28, 2026. Wilson Sonsini Goodrich & Rosati advised ESS Tech on the transaction.
Learn More
Image
Client Highlights
Wilson Sonsini Advises vTv on Expanded License Agreement with Newsoara
On February 2, 2026, vTv Therapeutics (vTv), a late-stage biopharmaceutical company focused on developing oral, small molecule drug candidates intended to help treat people living with diabetes and other chronic diseases, announced that it has expanded its license agreement with Newsoara Biopharma providing the company with global rights to vTv's phosphodiesterase type 4 (PDE4) inhibitor, HPP737. Wilson Sonsini Goodrich & Rosati advised vTv on the transaction.
Learn More
Image
Client Highlights
Wilson Sonsini Advises ALX Oncology on Public Offering
On January 30, 2026, ALX Oncology Holdings Inc., a clinical-stage biotechnology company focusing on novel therapies designed to treat cancer and extend patients’ lives, announced the pricing of an underwritten offering of 76,979,112 shares of common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase 18,574,120 shares of common stock in the offering. The gross proceeds of the offering are expected to be approximately $150 million before deducting the underwriting discounts and commissions and other estimated offering expenses, and excluding the exercise of any pre-funded warrants. Wilson Sonsini Goodrich & Rosati advised ALX Oncology on the transaction.
Learn More
Image
Client Highlights
Wilson Sonsini Advises Think Bioscience on Patent Matters Related to Oversubscribed $55 Million Series A
On January 20, 2026, Think Bioscience (Think Bio), a Boulder-based biotechnology company focused on unlocking elusive drug targets, has raised $55 million in an oversubscribed Series A. The round was led by Regeneron Ventures, Innovation Endeavors, and Janus Henderson Investors with participation from T.A. Springer, CE-Ventures, MBX Capital, and YK Bioventures. Returning investors include AV8 Ventures, CU Innovations, and Buff Gold Ventures. Wilson Sonsini Goodrich & Rosati advised Think Bio on patent matters related to the transaction.
Learn More
Image
Client Highlights
Wilson Sonsini Advises Zipline on $600 Million Financing
On January 21, 2026, Zipline, an American robotics company that designs, manufactures, and operates the world’s largest autonomous delivery system, announced that it has raised more than $600 million in financing, valuing the company at $7.6 billion. Wilson Sonsini Goodrich & Rosati advised Zipline on the transaction.

The funding includes participation from several existing and new investors, including Fidelity Management & Research Company, Baillie Gifford, Valor Equity Partners, and Tiger Global. Zipline will use the funds to accelerate its expansion into at least four new states this year, with Houston and Phoenix as the first two markets on that journey.

The Wilson Sonsini team that advised Zipline on the transaction includes David Wickwire, Jeana Kim, Rezwan Pavri, Kiri Yoshimura, Josh Gruenspecht, Sneha Dulski, and Barbara Mery.
Learn More
See More Leading Matters
Image
The Life Sciences Report – January 2026

This latest edition features articles on reasons for optimism around 2026 life sciences fundraising, key IP priorities for biotech and biopharma following Series B financing, the default rules of joint patent rights worldwide, the evolving role of innovation theories of harm in the antitrust analysis of life science mergers, life sciences venture financings for firm clients across 2H2024 and 1H2025, and how Wilson Sonsini helped ensure Light Horse Therapeutics’ impressive debut. The report also includes details on the most recent Biotech Summit and Phoenix Conference, the LaunchBio East Coast NextGen VC Forum, the latest episodes of the NextGen VC Podcast focused on life sciences investing, and the Patents and Innovations Library for in-house IP counsel, as well as select life sciences client highlights and upcoming events.

Read More
WSGR logo
Copyright © 2026 Wilson Sonsini Goodrich & Rosati. All Rights Reserved.